|  |
| --- |
| PROTOCOL TITLE: Kidney and Pancreas Post Transplant: COVID-19 Vaccination Guidelines for Post-Transplant Patients |
| **APPLICABLE FACILITIES:**[ ] EHC [ ] EDH [ ] EHH [ ] EHI [ ] EHN [ ] EJCH [ ] ELTAC [x] ESJH[x] EUH [ ] EUHM [ ] EUHS [ ] EUOSH [ ] EWWH [ ] RJV-ERH [ ] RJV-ESOP [ ] TEC/ESA |
| **EFFECTIVE DATE:** 11/10/2021 | **ORIGINATION DATE:** 10/6/2021 |

**CATEGORY:** Diagnostic/Therapeutic/Preventive Medication Guidelines

**LEVEL:** Independent

**SCOPE:** All transplant program physicians, practitioners and clinical staff members are responsible for compliance with this clinical protocol.

**PURPOSE:** Immunocompromised patients are vulnerable to COVID-19 infection. Studies indicate some immunocompromised people don’t always build the same level of immunity after vaccination and may benefit from an additional dose to ensure adequate protection against COVID-19.

**Vaccine Guidelines-**

|  |  |  |
| --- | --- | --- |
| Vaccine Type | **Vaccination Series** | **Booster** |
| **1st dose** | **2nd dose** | **3rd dose** |
| **Pfizer-BioNTech** | Needle with solid fill | 21 days after 1st dose | 28 days after 2nd dose | 6 months after 3rd dose |
| **Moderna** | Needle with solid fill | 28 days after 1st dose | 28 days after 2nd dose | 6 months after 3rd dose |
| **J&J** | Needle with solid fill | NA | NA | 2 months after 1st dose |

Special Patient Population

1. Fresh transplant patients:
* If unvaccinated pre-transplant, they are eligible to start the vaccination series 3 months after transplant
* If vaccinated with Pfizer pre-transplant, they are eligible to continue vaccination series and/or get the booster 3 months after transplant
1. Patients with recent rejection:
* Patients who received Thymoglobulin are eligible to start the vaccination series and/or get the booster 3 months after the last dose of Thymoglobulin
* Patients who received IVIG are eligible to start the vaccination series and/or get the booster 2 weeks after the last dose of IVIG
* Patients who received Plasmapheresis are eligible to start the vaccination series and/or get the booster anytime
1. Patients who receive Rituximab are eligible to start the vaccination series and/or get the booster after 4 weeks after the last dose of Rituximab
2. Patients who receive eculizumab are eligible to start the vaccination series and/or get the booster anytime
3. Patients who recovered from COVID-19 infection:
	1. If they received Monoclonal Ab, they are eligible to start the vaccination series and/or get the booster 3 months after the last dose of Monoclonal Ab
	2. If they received Remdesivir and dexamethasone, they are eligible to start the vaccination series and/or get the booster anytime

We advise immunocompromised patients to maintain personal measures to try to minimize exposure to COVID-19 (e.g., masking, distancing, avoiding crowds when possible) even after they are fully vaccinated because of the potential for reduced vaccine effectiveness. Household and other close contacts of immunocompromised patients should be vaccinated.

.

**RELATED POLICIES / PROCEDURES:**

Kidney and Pancreas Post-Transplant Management Care

**DEFINITIONS:** N/A

**REFERENCES AND SOURCES OF EVIDENCE:**

1. <https://www.cdc.gov/vaccines/covid-19/index.html>
2. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. Benotmane I, Gautier G, Perrin P, Olagne J, Cognard N, Fafi-Kremer S, Caillard S, JAMA. 2021
3. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.

Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, Selzner N, Schiff J, McDonald M, Tomlinson G, Kulasingam V, Kumar D, Humar A -N Engl J Med. 2021

**KEY WORDS:**